# US 2021/0070852 A1 · Anti-IL-23p19 Antibody Formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0070852 A1
- Document ID: US20210070852A1
- Status: Published application
- Kind: A1
- Application number: 17/014,399
- Filed: 2020-09-08
- Published: 2021-03-11
- Earliest claimed: 2019-09-09
- Assignees: Boehringer Ingelheim International GmbH
- Applicants: Boehringer Ingelheim International GmbH
- Inventors: Patrick Garidel; Torsten SCHULTZ-FADEMRECHT
- Web page: https://patentgrep.com/patent/US20210070852A1

## CPC

- C07K 16/244: {Interleukins [IL]}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 39/39591: {Stabilisation, fragmentation}
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 17/06: Antipsoriatics
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/51: Complete heavy chain or Fd fragment, i.e. VH + CH1
- C07K 2317/515: Complete light chain, i.e. VL + CL
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure inter alia provides a liquid pharmaceutical formulation comprising a) 150 mg/ml of an anti-IL-23p19 antibody, wherein the antibody comprises a light chain amino acid sequence according to SEQ ID NO: 1 and a heavy chain amino acid sequence according to SEQ ID NO: 2; b) a polyol; and c) a surfactant. The disclosed high concentration formulations are advantageously storage stable and suitable for subcutaneous administration.

## Claims

### Claim 1

A liquid pharmaceutical formulation comprising
a) 150 mg/ml of an anti-IL-23p19 antibody, wherein the antibody comprises a light chain amino acid sequence according to SEQ ID NO: 1 and a heavy chain amino acid sequence according to SEQ ID NO: 2;
b) a polyol; and
c) a surfactant.

### Claim 2 (depends on 1)

The formulation according to claim 1, comprising
d) a buffer.

### Claim 3 (depends on 1)

The formulation according to claim 1, wherein the antibody is risankizumab.

### Claim 4 (depends on 1)

The formulation according to claim 1, wherein the polyol is selected from a sugar, a sugar alcohol and combinations thereof.

### Claim 5 (depends on 4)

The formulation according to claim 4, wherein the polyol is selected from trehalose, sucrose, sorbitol, mannitol and combinations thereof.

### Claim 6 (depends on 1)

The formulation according to claim 1, wherein the concentration of the polyol in the formulation is at least 95 mM.

### Claim 7 (depends on 1)

The formulation according to claim 1, wherein the surfactant is a non-ionic surfactant.

### Claim 8 (depends on 1)

The formulation according to claim 1, wherein the concentration of the surfactant in the formulation is in a range of 0.05 mg/ml to 0.5 mg/ml.

### Claim 9 (depends on 1)

The formulation according to claim 1, wherein the pH of the liquid pharmaceutical formulation is in the range of pH 5.0 to 7.5, pH 5.0 to 7.0 or 5.2 to 6.5.

### Claim 10 (depends on 1)

The formulation according to claim 1, wherein the pH of the liquid pharmaceutical formulation is in a range of 5.2 to 6.2, 5.5 to 6.2, 5.5 to 5.9 or 5.6 to 5.8.

### Claim 11 (depends on 1)

The formulation according to claim 1, wherein the buffer has a pKa within 1.5 or one pH unit of the final pH of the liquid pharmaceutical formulation at 25° C.

### Claim 12 (depends on 1)

The formulation according to claim 1, wherein the buffer is selected from an acetate buffer, a succinate buffer or a histidine buffer.

### Claim 13 (depends on 1)

The formulation according to claim 1, wherein the buffer concentration is in the range of 3 mM to 50 mM or 5 mM to 25 mM or is 10 mM.

### Claim 14 (depends on 1)

The formulation according to claim 1, wherein the formulation is an aqueous formulation.

### Claim 15 (depends on 1)

The formulation according to claim 1, having one or more of the following characteristics:
(i) it comprises trehalose as polyol;
(ii) it comprises 185 mM trehalose as polyol;
(iii) it comprises 0.2 mg/ml polysorbate 20 as surfactant;
(iv) it comprises an acetate buffer;
(v) it comprises 5 mM to 25 mM buffer;
(vi) it comprises a single buffer;
(vii) the pH of the liquid pharmaceutical formulation is in a range of 5.2 to 6.2, 5.5 to 5.9 or 5.6 to 5.8; and/or
(viii) the pH of the liquid formulation is 5.7 or 6.2.

### Claim 16 (depends on 1)

The formulation according to claim 1, comprising
a) 150 mg/ml of the antibody;
b) a sugar;
c) a non-ionic surfactant; and
d) a buffer.

### Claim 17 (depends on 1)

The formulation according to claim 1, comprising
a) 150 mg/ml of the antibody;
b) trehalose;
c) a polysorbate; and
d) a buffer.

### Claim 18 (depends on 1)

The formulation according to claim 1, comprising
a) 150 mg/ml of the antibody;
b) 170 mM to about 200 mM trehalose;
c) 0.1 mg/ml to 0.3 mg/ml or 0.2 mg/ml polysorbate; and
d) a buffer.

### Claim 19 (depends on 1)

The formulation according to claim 1, comprising
a) 150 mg/ml of the antibody;
b) a polyol; and
c) a non-ionic surfactant; and
c) no buffer;
wherein the pH of the formulation is in a range of pH 5.2 to pH 6.5.

### Claim 20 (depends on 2)

The formulation according to claim 2, comprising
a) 150 mg/ml of the antibody;
b) 185 mM trehalose;
c) 0.2 mg/ml polysorbate 20; and
d) 10 mM acetate buffer;
wherein the pH is 5.7.

### Claim 21 (depends on 1)

The formulation according to claim 1, wherein the formulation is stable.

### Claim 22

A stable liquid pharmaceutical formulation comprising
a) 150 mg/ml of an anti-IL-23p19 antibody, wherein the antibody comprises a light chain amino acid sequence according to SEQ ID NO: 1 and a heavy chain amino acid sequence according to SEQ ID NO: 2;
b) a tonicity modifier; and
c) a surfactant,
wherein the formulation has a pH of 5.5-5.9 and the formulation is isotonic.

### Claim 23 (depends on 22)

The stable formulation according to claim 22, wherein the formulation has a pH of 5.7.

### Claim 24 (depends on 22)

The stable formulation according to claim 22, wherein the formulation has an osmolality of 290-320 mOsm/Kg.

### Claim 25 (depends on 22)

The stable formulation according to claim 22, comprising
d) a buffer, wherein the buffer is in the range of 3 mM to 50 mM or 5 mM to 25 mM or is 10 mM.

### Claim 26 (depends on 22)

The stable formulation according to claim 22, wherein the formulation is buffer-free.

### Claim 27 (depends on 22)

The stable formulation according to claim 22, wherein the tonicity modifier is a polyol.

### Claim 28 (depends on 27)

The stable formulation according to claim 27, wherein the polyol is selected from a sugar, a sugar alcohol and combinations thereof or selected from trehalose, sucrose, sorbitol, mannitol and combinations thereof.

### Claim 29 (depends on 22)

The stable formulation according to claim 22, having one or more of the following characteristics:
(i) the surfactant is a non-ionic surfactant;
(ii) the surfactant is a polysorbate; and/or
(iii) wherein the concentration of the surfactant in the formulation is in a range of 0.05 mg/ml to 0.5 mg/ml.

### Claim 30 (depends on 22)

The stable formulation according to claim 22, wherein the antibody is risankizumab.

### Claim 31 (depends on 22)

The formulation according to claim 22, fulfilling one or more of the following stability characteristics:
(i) following storage at 5° C. for 24 months, at least 94%, at least 95% or at least 96% of the antibody is present as a monomer as measured by UP-SEC, and/or the relative monomer content of the antibody does not decrease by more than 3%, more than 2%, more than 1.5% or more than 1%;
(ii) following storage at 5° C. for 9 months, at least 96% or at least 96.5% of the antibody is present as a monomer as measured by UP-SEC, and/or the relative monomer content of the antibody does not decrease by more than 1.5% or more than 1%;
(iii) following storage at 5° C. for 3 months, at least 96% or at least 97% of the antibody is present as a monomer as measured by UP-SEC, and/or the relative monomer content of the antibody does not decrease by more than 1% or more than 0.7% or more than 0.5%;
(iv) following storage at 25° C. for 12 months, at least 90% or at least 92% of the antibody is present as a monomer as measured by UP-SEC, and/or the relative monomer content of the antibody does not decrease by more than 7% or more than 6% or more than 5%;
(v) following storage at 25° C. for 3 months, at least 95% of the antibody is present as a monomer as measured by UP-SEC, and/or the relative monomer content of the antibody does not decrease by more than 3% or more than 2%;
(vi) following storage at 25° C. for 1 month, at least 96% of the antibody is present as a monomer as measured by UP-SEC, and/or the relative monomer content of the antibody does not decrease by more than 2% or more than 1%;
(vii) following storage at 40° C. for 3 months, at least 87% or at least 88% of the antibody is present as a monomer as measured by UP-SEC, and/or the relative monomer content of the antibody does not decrease by more than 10% or more than 9% or more than 8%; and/or
(viii) following storage at 40° C. for 1 month, at least 93% or at least 94% of the antibody is present as a monomer as measured by UP-SEC, and/or the relative monomer content of the antibody does not decrease by more than 5% or more than 4%.

### Claim 32 (depends on 22)

The formulation according to claim 22, fulfilling one or more of the following stability characteristics:
(i) following storage at 5° C. for at least 3, 6, 9, 12, 18 or 24 months, the formulation has an opalescence of 12 FNU (Formazin Nephelometry Units) or less or 10 FNU or less, and/or the opalescence does not increase by more than 5 FNU or more than 3 FNU;
(ii) following storage at 25° C. for at least 1, 3, 6, 9 or 12 months, the formulation has an opalescence of 12 FNU or less or 10 FNU or less, and/or the opalescence does not increase by more than 7 FNU or more than 5 FNU;
(iii) following storage at 40° C. for at least 1 or 3 months, the formulation has an opalescence of 12 FNU or less or 10 FNU or less, and/or the opalescence does not increase by more than 5 FNU or more than 3 FNU; and/or
(iv) following shaking at 25° C. for 21 days, the formulation has an opalescence of 12 FNU or less or 10 FNU or less, and/or the opalescence of the formulation does not increase by more than 3 FNU or more than 2 FNU.

### Claim 33 (depends on 22)

The formulation according to claim 22, fulfilling one or both of the following stability characteristics:
(i) following shaking at 25° C. for 21 days, at least 95% or at least 96% of the antibody is present as a monomer as measured by UP-SEC, and/or the relative monomer content of the antibody does not decrease by more than 2% or more than 1%; and/or
(ii) following shaking at 25° C. for 21 days, less than 3% or less than 2% of the antibody is present as high molecular weight (HMW) species as measured by UP-SEC, and/or the relative HMW content of the antibody does not increase by more than 2% or more than 1.5% or more than 1%.

### Claim 34 (depends on 22)

The formulation according to claim 22, fulfilling one or more of the following stability characteristics:
(i) following storage at 5° C. for 24 months, less than 4% or less than 3% of the antibody is present as high molecular weight (HMW) species as measured by UP-SEC, and/or the relative HMW content of the antibody does not increase by more than 2% or more than 1.5% or more than 1%;
(ii) following storage at 5° C. for 9 months, less than 4% or less than 3% or less than 2.5% of the antibody is present as high molecular weight (HMW) species as measured by UP-SEC, and/or the relative HMW content of the antibody does not increase by more than 1% or more than 0.8% or more than 0.6%;
(iii) following storage at 5° C. for 3 months, less than 4% or less than 3% or less than 2.5% of the antibody is present as high molecular weight (HMW) species as measured by UP-SEC, and/or the relative HMW content of the antibody does not increase by more than 1% or more than 0.8% or more than 0.6%;
(iv) following storage at 25° C. for 12 months, less than 5% or less than 4% of the antibody is present as high molecular weight (HMW) species as measured by UP-SEC, and/or the relative HMW content of the antibody does not increase by more than 3% or more than 2.5% or more than 2%;
(v) following storage at 25° C. for 3 months, less than 4% or less than 3.5% or less than 3.2% of the antibody is present as high molecular weight (HMW) species as measured by UP-SEC, and/or the relative HMW content of the antibody does not increase by more than 2% or more than 1.5%;
(vi) following storage at 25° C. for 1 month, less than 4% or less than 3.5% or less than 3% of the antibody is present as high molecular weight (HMW) species as measured by UP-SEC, and/or the relative HMW content of the antibody does not increase by more than 1.5% or more than 1%;
(vii) following storage at 40° C. for 3 months, less than 6.5% or less than 6% or less than 5.5% of the antibody is present as a high molecular weight (HMW) species as measured by UP-SEC, and/or the relative HMW content of the antibody does not increase by more than 5% or more than 4%; and/or
(viii) following storage at 40° C. for 1 month, less than 5% or less than 4.5% or less than 4% of the antibody is present as high molecular weight (HMW) species as measured by UP-SEC, and/or the relative HMW content of the antibody does not increase by more than 2.5% or more than 2%.

### Claim 35 (depends on 1)

The formulation according to claim 1, wherein the formulation is suitable for injection.

### Claim 36 (depends on 1)

The formulation according to claim 1, having one or more of the following characteristics:
(i) wherein the formulation is not and has not been subjected to a reconstitution step before use;
(ii) wherein the liquid pharmaceutical formulation does not comprise sorbitol;
(iii) it does not comprise arginine;
(iv) it does not comprise an amino acid with a positive-charged side chain;
(v) it does not comprise an amino acid with a charged side chain;
(vi) it does not comprise methionine; and/or
(vii) it does not comprise an amino acid as additive.

### Claim 37 (depends on 1)

A sealed container containing the pharmaceutical formulation of claim 1.

### Claim 38 (depends on 1)

A method of treating a disease in a human subject, comprising administering to a human subject with a disease selected from psoriasis, inflammatory bowel disease, psoriatic arthritis, and Crohn's disease the pharmaceutical formulation according to claim 1.

### Claim 39 (depends on 4)

The formulation according to claim 4, wherein the polyol is trehalose.

### Claim 40 (depends on 1)

The formulation according to claim 1, wherein the concentration of the polyol in the formulation is within the range of 125 mM to 250 mM.

### Claim 41 (depends on 1)

The formulation according to claim 1, wherein the concentration of the polyol in the formulation is within the range of 145 mM to 225 mM.

### Claim 42 (depends on 1)

The formulation according to claim 1, wherein the non-ionic surfactant is a polysorbate.

### Claim 43 (depends on 1)

The formulation according to claim 1, wherein the concentration of the surfactant in the formulation is in a range of 0.075 mg/ml to 0.4 mg/ml.

### Claim 44 (depends on 1)

The formulation according to claim 1, wherein the concentration of the surfactant in the formulation is in a range of 0.1 mg/ml to 0.3 mg/ml.

### Claim 45 (depends on 1)

The formulation according to claim 1, wherein the pH of the liquid pharmaceutical formulation is 5.7.

### Claim 46 (depends on 1)

The formulation according to claim 1, wherein the buffer has a pKa within the range of pH 4.2-7.2, 4.5 to 7 at 25° C.

### Claim 47 (depends on 1)

The formulation according to claim 1, wherein the buffer has a pKa within the range of pH 4.6 to 5.8 at 25° C.

### Claim 48 (depends on 1)

The formulation according to claim 1, wherein the buffer is an acetate buffer.

### Claim 49 (depends on 15)

The formulation according to claim 15, wherein the buffer concentration is 10 mM.

### Claim 50 (depends on 15)

The formulation according to claim 15, wherein the buffer is an acetate buffer

### Claim 51 (depends on 16)

The formulation according to claim 16, wherein the concentration of the sugar is in the range of 145 mM to 225 mM.

### Claim 52 (depends on 16)

The formulation according to claim 16, wherein the concentration of the non-ionic surfactant is in the range of 0.05 mg/ml to 0.5 mg/ml.

### Claim 53 (depends on 16)

The formulation according to claim 16, wherein the concentration of the non-ionic surfactant is in the range of 0.075 mg/ml to 0.3 mg/ml.

### Claim 54 (depends on 16)

The formulation according to claim 16, wherein the pH of the formulation is in a range of pH 5.2 to pH 6.5, 5.2 to 6.2 or 5.5 to 6.2.

### Claim 55 (depends on 17)

The formulation according to claim 17, wherein the concentration of trehalose is in the range of 145 mM to 225 mM.

### Claim 56 (depends on 17)

The formulation according to claim 17, wherein the polysorbate concentration is in the range of 0.05 mg/ml to 0.5 mg/ml.

### Claim 57 (depends on 17)

The formulation according to claim 17, wherein the polysorbate concentration is in the range of 0.075 mg/ml to 0.3 mg/ml.

### Claim 58 (depends on 17)

The formulation according to claim 17, wherein the pH of the formulation is in a range of pH 5.2 to pH 6.5.

### Claim 59 (depends on 17)

The formulation according to claim 17, wherein the pH of the formulation is in a range of pH 5.5 to pH 6.2.

### Claim 60 (depends on 18)

The formulation according to claim 18, wherein the polysorbate is polysorbate 20.

### Claim 61 (depends on 18)

The formulation according to claim 18, wherein the buffer is an acetate buffer.

### Claim 62 (depends on 18)

The formulation according to claim 18, wherein the pH of the formulation is in a range of pH 5.2 to pH 6.5.

### Claim 63 (depends on 18)

The formulation according to claim 18, wherein the pH of the formulation is in a range of pH 5.5 to pH 6.2.

### Claim 64 (depends on 19)

The formulation according to claim 19, wherein the polyol is a sugar or sugar alcohol.

### Claim 65 (depends on 19)

The formulation according to claim 19, wherein the non-ionic surfactant is a polysorbate.

### Claim 66 (depends on 19)

The formulation according to claim 19, wherein the pH of the formulation is in a range of pH 5.5 to pH 6.2.

### Claim 67 (depends on 25)

The stable formulation according to claim 25, wherein the buffer has a pKa within 1.5 or one pH unit of the final pH of the liquid pharmaceutical formulation at 25° C.

### Claim 68 (depends on 25)

The stable formulation according to claim 25, wherein the buffer has a pKa within the range of pH 4.2-7.2, 4.5 to 7 or 4.6 to 5.8 at 25° C.

### Claim 69 (depends on 25)

The stable formulation according to claim 25, wherein the buffer is selected from an acetate buffer, a succinate buffer or a histidine buffer.

### Claim 70 (depends on 27)

The stable formulation according to claim 27, wherein the formulation comprises wherein the concentration of the polyol in the formulation is at least 95 mM.

### Claim 71 (depends on 27)

The stable formulation according to claim 27, wherein the concentration of the polyol in the formulation is within the range of 125 mM to 250 mM.

### Claim 72 (depends on 27)

The stable formulation according to claim 27, wherein the concentration of the polyol in the formulation is within the range of 145 mM to 225 mM.

### Claim 73 (depends on 29)

The stable formulation according to claim 29, wherein the polysorbate is selected from polysorbate 20 and polysorbate 80.

### Claim 74 (depends on 29)

The stable formulation according to claim 29, wherein the concentration of the surfactant in the formulation is in a range of 0.075 mg/ml to 0.4 mg/ml.

### Claim 75 (depends on 29)

The stable formulation according to claim 29, wherein the concentration of the surfactant in the formulation is in a range of 0.1 mg/ml to 0.3 mg/ml.

### Claim 76 (depends on 35)

The formulation according to claim 35, wherein the formulation is suitable for subcutaneous injection.

### Claim 77 (depends on 37)

The sealed container according to claim 37, wherein the container is a vial or pre-filled syringe.
